Cardiovascular Division, Boston University Medical Center, Boston, Massachusetts; Boston University School of Medicine, Boston, Massachusetts; Cardiovascular Division, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Am J Cardiol. 2023 Oct 15;205:425-430. doi: 10.1016/j.amjcard.2023.07.172. Epub 2023 Sep 4.
Endovascular revascularization of the superficial femoral artery (SFA) may lead to recurrent ischemic syndromes, revascularization, or amputation. The impact of these events on mortality is unknown. We followed all patients having SFA endovascular revascularization for claudication or chronic limb-threatening ischemia in 2 cardiovascular (CV) divisions in Boston, Massachusetts. Any recurrent limb event after the initial SFA revascularization included recurrent claudication (67%), limb ulceration or gangrene (13%), repeat endovascular revascularization (61%), surgical revascularization (15%), or major (9%) or minor amputation (8%). We linked data to the National Death Index to ascertain cause of death grouped into CV mortality, or non-CV mortality. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) from Cox proportional hazards and sub-HRs from Fine-Gray competing risks analyses were clustered by patient. Overall, there were 202 patients with 253 index limb endovascular procedures. A recurrent limb event occurred in 123 limbs (49%) and 93 patients (46%). Patients with and without recurrent limb events had similar numbers of deaths over follow-up (76 [62%] vs 71 [55%], respectively). In multivariable models, recurrent limb event was not related to all-cause death (HR 0.92, 95% CI 0.64 to 1.33), CV death (HR 1.29, 95% CI 0.72 to 1.30), or non-CV death (HR 0.65, CI 0.39 to 1.07). Competing risk analyses suggested male gender and chronic limb-threatening ischemia were more strongly related to CV death, and chronic kidney more strongly related to disease to non-CV death. In conclusion, recurrent limb events, which contribute to patient morbidity, do not increase the risk of all-cause or cause-specific mortality, and should not discourage repeat revascularization to relieve symptoms or ischemia.
股浅动脉(SFA)的血管内再血管化可能导致复发性缺血综合征、再血管化或截肢。这些事件对死亡率的影响尚不清楚。我们对在马萨诸塞州波士顿的 2 个心血管(CV)科室接受 SFA 血管内再血管化治疗跛行或慢性肢体威胁性缺血的所有患者进行了随访。初始 SFA 再血管化后的任何复发性肢体事件包括复发性跛行(67%)、肢体溃疡或坏疽(13%)、重复血管内再血管化(61%)、手术再血管化(15%)或大(9%)或小截肢(8%)。我们将数据与国家死亡索引相关联,以确定死因分为心血管死亡率或非心血管死亡率。Cox 比例风险和 Fine-Gray 竞争风险分析的亚风险比(HR)和 95%置信区间(95%CI)按患者聚类。总体而言,有 202 名患者接受了 253 次指数肢体血管内手术。123 条肢体(49%)和 93 名患者(46%)发生了复发性肢体事件。在随访期间,有和没有复发性肢体事件的患者的死亡人数相似(分别为 76 [62%]和 71 [55%])。在多变量模型中,复发性肢体事件与全因死亡(HR 0.92,95%CI 0.64 至 1.33)、心血管死亡(HR 1.29,95%CI 0.72 至 1.30)或非心血管死亡(HR 0.65,CI 0.39 至 1.07)无关。竞争风险分析表明,男性和慢性肢体威胁性缺血与心血管死亡的关系更为密切,而慢性肾脏病与非心血管死亡的关系更为密切。总之,导致患者发病率增加的复发性肢体事件并不会增加全因或病因特异性死亡率的风险,也不应劝阻再次进行血管重建以缓解症状或缺血。